Treating high triglyceride levels reduces the risk of heart disease
While observational and genetic studies link high triglycerides to cardiovascular disease, clinical trials testing triglyceride-lowering therapies have yielded inconsistent results regarding cardiovascular risk reduction.
Although genetic and epidemiological data strongly support a mechanistic and causal link between triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease, interventional clinical trials have shown mixed results. While targeted therapies like icosapent ethyl have demonstrated cardiovascular benefit (often via pleiotropic mechanisms beyond simple triglyceride reduction), major trials of fibrates and other mixed omega-3 formulations have failed to reduce cardiovascular events. Therefore, the claim that treating high triglycerides reliably reduces heart disease risk remains contested in the literature.
The evidence we hold leans evenly split
How this was weighed
official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x
- Do triglyceride-lowering drugs decrease risk of cardiovascul · peer-reviewed · supports · weight 1.3 · 2017
- Pemafibrate and other triglyceride-lowering therapies to red · peer-reviewed · supports · weight 1.05 · 2024
- 2025: The year in cardiovascular disease – the year of trigl · peer-reviewed · supports · weight 1.05 · 2025
- Pemafibrate and other triglyceride-lowering therapies to red · peer-reviewed · refutes · weight 1.05 · 2024
- Lipid management in type 2 diabetes and non-HDL-cholesterol: · peer-reviewed · refutes · weight 1.05 · 2026
- Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causa · peer-reviewed · refutes · weight 1 · 2026
- Rethinking triglycerides in the management of ASCVD. · peer-reviewed · refutes · weight 1 · 2026
Kevin C. Maki, Mary R. Dicklin. Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. 2017. https://doi.org/10.1097/mol.0000000000000424
Subgroup and observational data suggest that lowering triglycerides and remnant lipoproteins is associated with reduced cardiovascular risk.
Michael Miller. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. 2024. https://doi.org/10.1097/hco.0000000000001136
Several prominent clinical trials, such as STRENGTH and PROMINENT, failed to show that lowering triglycerides translated to reduced cardiovascular events.
See more details
Michael Miller. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. 2024. https://doi.org/10.1097/hco.0000000000001136
The REDUCE-IT trial demonstrated significant cardiovascular risk reduction using icosapent ethyl in hypertriglyceridemic patients.
Peter P. Toth, Maciej Banach. 2025: The year in cardiovascular disease – the year of triglyceride lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?. 2025. https://doi.org/10.5114/aoms/216960
Certain targeted therapies like icosapent ethyl and fenofibrate are endorsed in guidelines to address residual cardiovascular risk in high-risk patients with elevated triglycerides.
Brandts J, Verket M, Zambon A, Marx N, Müller-Wieland D, Federici M. Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.. 2026. https://doi.org/10.1186/s12933-026-03166-4
The impact of conventional triglyceride-lowering therapies like omega-3 fatty acids and fibrates on cardiovascular outcomes remains uncertain.
Björnson E, Adiels M. Triglyceride-Rich Lipoproteins and ASCVD: Evidence for Causality and Challenges in Therapeutic Translation.. 2026. https://doi.org/10.1007/s11883-026-01442-y
Therapeutic translation has been inconsistent, and agents like icosapent ethyl may reduce cardiovascular events through mechanisms independent of pure triglyceride lowering.
Khanna S, Bhatt DL, Libby P, Bhat A. Rethinking triglycerides in the management of ASCVD.. 2026. https://doi.org/10.1093/eurjpc/zwag341
Reducing triglyceride concentrations alone does not consistently decrease cardiovascular events, indicating they act more as markers of remnant particle burden rather than direct therapeutic targets.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt